hap

Join us as we delve into the remarkable story of R.G. Chandramogan, who went from selling ice cream on pushcarts in the 1970s to becoming the chairman of India's largest private-sector dairy company, Hatsun Agro. Discover his pioneering journey in the world of dairy, entrepreneurship, and resilience. With a 7,000+ crore revenue company, Chandramogan's insights and determination to build a generational business are truly inspiring. 

#HatsunAgro #DairySuccess #EntrepreneurJourney #Resilience #GenerationalBusiness #PodcastEpisode

In this exclusive teaser, we delve into the inspiring journey of R.G. Chandramogan, the mastermind behind Hatsun, one of India's leading dairy companies. Discover what fueled his courage to embark on this incredible journey and how he turned a barren village into a hub of prosperity. Join us in uncovering the invaluable lessons that shaped the early years of Hatsun's rise to success. Stay tuned for the full episode on November 1st at 10 AM.

#HatsunAgro #HAP #IBACO #ArunIcecream #Entrepreneurship #SuccessStory #PodcastTeaser

In this episode, David van Duin, MD, PhD, FIDSA, FAST, discusses new data on complicated clinical infections presented at ECCMID 2023, including:

• Gram-negative resistance
  • Pharmacokinetic and clinical outcomes in patients receiving meropenem/vaborbactam for KPC-producing carbapenem-resistant Enterobacterales infections
  • Comparative study of cefiderocol- vs colistin-containing regimens for CRAB VAP with concomitant bacteremia
  • Real-world use of imipenem/cilastatin/relebactam for the treatment of infections caused by multidrug-resistant organisms
• Antimicrobial stewardship
  • Safety and efficacy of antibiotic de-escalation from an antipseudomonal β-lactam in patients with Enterobacterales BSIs in SIMPLIFY
  • The SOAB study comparing clinical outcomes of switching to oral antibiotics after IV lead-in therapy vs continuing IV therapy in patients with Enterobacterales BSIs
  • Data from REGARD-VAP on outcomes of shortened antibiotic treatment for VAP guided by clinical criteria
• Investigational agents
  • Open-label study following ATTACK of patients with colistin-resistant CRAB infections receiving sulbactam/durlobactam
  • Summary of findings from EAGLE-2 and EAGLE-3 of gepotidacin for uncomplicated UTI treatment
  • Post hoc DOOR analysis of SURE-2 of sulopenem for the treatment of complicated UTIs

Faculty: 
David van Duin, MD, PhD, FIDSA, FAST 
Professor of Medicine 
Director, Immunocompromised Host Infecious Diseases Program 
Division of Infectious Diseases 
University of North Carolina 
Chapel Hill, North Carolina 

Content based on an online CME/CE program supported by an independent educational grant from Shionogi Inc. 

Link to full program: https://bit.ly/3niXGJ6

Link to downloadable slides: https://bit.ly/3Hx0ppn

See omnystudio.com/listener for privacy information.

In this episode, Keith S. Kaye, MD, MPH; Lilian Abbo, MD, FIDSA; and Jason M. Pogue, PharmD, discuss HABP/VABP and gram-negative resistance including:

• Epidemiology and burden of nosocomial bacterial pneumonia
• Patient-specific risk factors for MDR pathogens
• Improving outcomes with the use of antibiograms
• Recommended empiric therapy for clinically suspected VABP
• Antimicrobial resistance in HABP/VABP
• Algorithms for gram-negative organism antibiotic-susceptibility testing
• Using rapid diagnostic tests for HABP/VABP
• New antimicrobial agents for MDR gram-negative infections with discussion of the 2021 IDSA guidance, and the following studies:
  • ASPECT-NP: ceftolozane/tazobactam vs meropenem
  • REPROVE: ceftazidime/avibactam vs meropenem
  • RESTORE-IMI-1 imipenem/cilastatin/relebactam vs colistin + imipenem
  • RESTORE-IMI-2: imipenem/cilastatin/relebactam vs piperacillin/tazobactam
  • APEKS-NP: cefiderocol vs meropenem
  • CREDIBLE-CR: cefiderocol vs best available therapy

Program Director:

Keith S. Kaye, MD, MPH
Chief
Division of Allergy, Immunology and Infectious Diseases
Professor of Medicine
Rutgers Robert Wood Johnson 
Medical School
New Brunswick, New Jersey

Faculty:

Lilian Abbo, MD, FIDSA
Associate Chief Medical Officer in Infectious Diseases
Jackson Health System
Professor of Infectious Diseases
Department of Medicine & Miami Transplant Institute
University of Miami Miller School of Medicine
Miami, Florida

Jason M. Pogue, PharmD
Clinical Professor
Department of Clinical Pharmacy
University of Michigan College of Pharmacy
Infectious Diseases Clinical Pharmacist
Michigan Medicine
Ann Arbor, Michigan

Content based on a CME program supported by an educational grant from Merck Sharp & Dohme Corp.

Follow along with a downloadable slideset at:
https://bit.ly/3CEop6h

Link to full program
 https://bit.ly/3i781lf

It's finally (almost!) time to leave cursed 2020 behind us! Celebrate the coming of a new year with your favorite best exes, even though Gabe got confused and mixed up some dates. This week's episode also brings you round two of Convincing People of Conspiracies with Colton! Will Earth explode? Were Adam and Even martians?! Listen to find out (sort of)!